Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
drospirenone + ethinyl estradiol + levomefolate calcium
- Development stage
- Approved
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Drospirenone + ethinyl estradiol + levomefolate calcium is an oral fixed-dose combination pharmaceutical containing the progestin drospirenone, the estrogen ethinyl estradiol, and levomefolate calcium, the bioactive folate form of vitamin B9. It is marketed as a combined oral contraceptive and folate-containing formulation used primarily to prevent pregnancy by suppressing ovulation, while also increasing cervical mucus viscosity and altering the endometrium; the drospirenone component also contributes progestogenic, antiandrogenic, and antimineralocorticoid pharmacology. Depending on the specific branded product, it has been approved for pregnancy prevention and folate supplementation to reduce the risk of neural tube defects in pregnancies conceived during or shortly after use, and certain versions such as Beyaz are also approved for treatment of premenstrual dysphoric disorder and moderate acne vulgaris in appropriate females of reproductive potential.
- Brand names
- BeyazSafyralTydemy
- Other names
- drospirenone/ethinyl estradiol/levomefolate calciumdrospirenone, ethinyl estradiol and levomefolate calcium tablets and levomefolate calcium tablets
02
Targets
MR (Mineralocorticoid receptor)ER (Estrogen receptor)PR (Progesterone receptor)AR (Adrenergic receptors)
Beyond the preview
Go deeper on drospirenone + ethinyl estradiol + levomefolate calcium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on drospirenone + ethinyl estradiol + levomefolate calcium.